Galectin Therapeutics reports Q3 net loss of $11.2M; NAVIGATE trial top-line results expected Dec 2024

GALECTIN THERAPEUTICS INC

2024-Q3 EPS reported -$0.57

Net loss $11.2M ($0.18/share) vs $14.0M ($0.24) in Q3 2023; R&D expense $7.6M, G&A $1.5M.
Cash $27.1M at Sept 30, 2024; $6M credit line from chairman; runway through May 2025.
NAVIGATE trial of belapectin in MASH cirrhosis top-line efficacy/safety results expected December 2024.
Three belapectin abstracts accepted for poster presentation at AASLD 2024 annual meeting.
Annual stockholder meeting set for January 23, 2025 due to NAVIGATE trial timing.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.